## CITATION REPORT List of articles citing

Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent

DOI: 10.4155/bio-2021-0039 Bioanalysis, 2021, 13, 711-724.

Source: https://exaly.com/paper-pdf/80440235/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum Journal of Mass Spectrometry and Advances in the Clinical Lab, 2022, 24, 15-21		Ο
7	Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib <i>European Journal of Clinical Pharmacology</i> , <b>2022</b> ,	2.8	O
6	A New Lc-Ms/Ms Method for the Simultaneous Quantification of Abemaciclib, its Main Active Metabolites M2 and M20, and Letrozole for Therapeutic Drug Monitoring. SSRN Electronic Journal,	1	
5	Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , <b>2022</b> ,	14	O
4	A new LC-MS/MS method for the simultaneous quantification of abemaciclib, its main active metabolites M2 and M20, and letrozole for therapeutic drug monitoring <b>2022</b> , 1207, 123403		O
3	Development and validation of a reversed-phase high-performance liquid chromatographyIltraviolet method for abemaciclib-related substance detection in bulk drugs.		O
2	Therapeutic Drug Monitoring in Breast Cancer Therapy ILC-MS/MS method for quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, ribociclib, and major metabolites abemaciclib M20 and M2 in human serum. <b>2022</b> , 115211		O
1	Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis.		1